Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)
NCT02452294Phase 2Unknown
- Sponsor
- University Hospital Tübingen
- Start
- Jul 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of buparlisib in melanoma, sponsored by University Hospital Tübingen. Primary endpoint: Intracranial disease control rate at 6 weeks. Status: unknown.
02
Drugs
buparlisib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02452294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452294.